Comparing comparators: A look at control arms in kidney cancer studies over the years

S. Bracarda, C. Porta, M. Sisani, F. Marrocolo, C. Paglino, A. Hamzaj, S. D. Buono, C. N. Sternberg

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In the past decade, an increasing number of frequently positive randomised clinical trials have been completed, allowing new consideration of the present therapeutic armamentarium for advanced renal cell carcinoma. These studies were predominantly designed to compare the experimental drugs with 1 of 2 active control arms: interferon alpha-2a or sorafenib. Different from expectations, the final results of some of these studies were not in line with the predictions, and the reasons have not been fully investigated. Consequently, there is a great need for careful analysis of the studies carried out so far, chiefly the role and validity of the control arms. In this regard, the examination of patient baseline characteristics and other factors of potential interest seems fundamental for a correct analysis of the results of these trials and consequent optimal use of the available targeted agents.

Original languageEnglish
Pages (from-to)14-19
Number of pages6
JournalBritish Journal of Cancer
Volume112
Issue number1
DOIs
Publication statusPublished - Jan 6 2015

Fingerprint

Kidney Neoplasms
Renal Cell Carcinoma
Randomized Controlled Trials
Pharmaceutical Preparations
Therapeutics
interferon alfa-2a
sorafenib

Keywords

  • antiangiogenic therapy
  • interferon
  • renal cell carcinoma
  • sorafenib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Bracarda, S., Porta, C., Sisani, M., Marrocolo, F., Paglino, C., Hamzaj, A., ... Sternberg, C. N. (2015). Comparing comparators: A look at control arms in kidney cancer studies over the years. British Journal of Cancer, 112(1), 14-19. https://doi.org/10.1038/bjc.2014.240

Comparing comparators : A look at control arms in kidney cancer studies over the years. / Bracarda, S.; Porta, C.; Sisani, M.; Marrocolo, F.; Paglino, C.; Hamzaj, A.; Buono, S. D.; Sternberg, C. N.

In: British Journal of Cancer, Vol. 112, No. 1, 06.01.2015, p. 14-19.

Research output: Contribution to journalArticle

Bracarda, S, Porta, C, Sisani, M, Marrocolo, F, Paglino, C, Hamzaj, A, Buono, SD & Sternberg, CN 2015, 'Comparing comparators: A look at control arms in kidney cancer studies over the years', British Journal of Cancer, vol. 112, no. 1, pp. 14-19. https://doi.org/10.1038/bjc.2014.240
Bracarda, S. ; Porta, C. ; Sisani, M. ; Marrocolo, F. ; Paglino, C. ; Hamzaj, A. ; Buono, S. D. ; Sternberg, C. N. / Comparing comparators : A look at control arms in kidney cancer studies over the years. In: British Journal of Cancer. 2015 ; Vol. 112, No. 1. pp. 14-19.
@article{7fff03a33315481b8387c8238326ce4c,
title = "Comparing comparators: A look at control arms in kidney cancer studies over the years",
abstract = "In the past decade, an increasing number of frequently positive randomised clinical trials have been completed, allowing new consideration of the present therapeutic armamentarium for advanced renal cell carcinoma. These studies were predominantly designed to compare the experimental drugs with 1 of 2 active control arms: interferon alpha-2a or sorafenib. Different from expectations, the final results of some of these studies were not in line with the predictions, and the reasons have not been fully investigated. Consequently, there is a great need for careful analysis of the studies carried out so far, chiefly the role and validity of the control arms. In this regard, the examination of patient baseline characteristics and other factors of potential interest seems fundamental for a correct analysis of the results of these trials and consequent optimal use of the available targeted agents.",
keywords = "antiangiogenic therapy, interferon, renal cell carcinoma, sorafenib",
author = "S. Bracarda and C. Porta and M. Sisani and F. Marrocolo and C. Paglino and A. Hamzaj and Buono, {S. D.} and Sternberg, {C. N.}",
year = "2015",
month = "1",
day = "6",
doi = "10.1038/bjc.2014.240",
language = "English",
volume = "112",
pages = "14--19",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Comparing comparators

T2 - A look at control arms in kidney cancer studies over the years

AU - Bracarda, S.

AU - Porta, C.

AU - Sisani, M.

AU - Marrocolo, F.

AU - Paglino, C.

AU - Hamzaj, A.

AU - Buono, S. D.

AU - Sternberg, C. N.

PY - 2015/1/6

Y1 - 2015/1/6

N2 - In the past decade, an increasing number of frequently positive randomised clinical trials have been completed, allowing new consideration of the present therapeutic armamentarium for advanced renal cell carcinoma. These studies were predominantly designed to compare the experimental drugs with 1 of 2 active control arms: interferon alpha-2a or sorafenib. Different from expectations, the final results of some of these studies were not in line with the predictions, and the reasons have not been fully investigated. Consequently, there is a great need for careful analysis of the studies carried out so far, chiefly the role and validity of the control arms. In this regard, the examination of patient baseline characteristics and other factors of potential interest seems fundamental for a correct analysis of the results of these trials and consequent optimal use of the available targeted agents.

AB - In the past decade, an increasing number of frequently positive randomised clinical trials have been completed, allowing new consideration of the present therapeutic armamentarium for advanced renal cell carcinoma. These studies were predominantly designed to compare the experimental drugs with 1 of 2 active control arms: interferon alpha-2a or sorafenib. Different from expectations, the final results of some of these studies were not in line with the predictions, and the reasons have not been fully investigated. Consequently, there is a great need for careful analysis of the studies carried out so far, chiefly the role and validity of the control arms. In this regard, the examination of patient baseline characteristics and other factors of potential interest seems fundamental for a correct analysis of the results of these trials and consequent optimal use of the available targeted agents.

KW - antiangiogenic therapy

KW - interferon

KW - renal cell carcinoma

KW - sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84920665971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920665971&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.240

DO - 10.1038/bjc.2014.240

M3 - Article

C2 - 25375270

AN - SCOPUS:84920665971

VL - 112

SP - 14

EP - 19

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -